Variety of qualified sufferers: CDEC reviewed the uncertainty in the quantity of clients with reasonably significant to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients who're categorized as getting mild or avera